Treatment can begin with small changes

Home care can ease soreness without giving up movement

Pacing means breaking a hard task into shorter parts. It can prevent one busy morning from causing days of worse soreness. Gentle strength work can support the joint and steady your movement. A cane or brace may lower the load while you walk.

Medicine may help, but the risks differ among people. A cream on the sore area may affect you differently than a pill. Your doctor can check your health and the medicines you already take. Don't change prescribed medicine on your own.

Ask how many days to try each home step. During that time, track soreness and one daily task. Stop sooner and call if pain turns sharp or swelling rises. This shows whether the home care is helping you move more easily.

The exam comes before an office procedure

A visit begins with your soreness and a joint exam. The clinician checks tender areas, swelling, motion, and strength. An X-ray may show old wear or injury. These findings may lead to physical therapy, medicine, or an office procedure.

The letters PRP mean platelet-rich plasma. An office draws some of your blood and uses a spinning machine to collect platelets. Concentrated PRP holds more platelets in the amount used. For bone marrow concentrate, an office draws liquid from the pelvis bone through a needle. The clinic spins that liquid and puts the concentrated portion into your aching joint.

Ask which procedure is planned and who will perform it.

QC Kinetix can discuss office care when soreness stays

QC Kinetix offers regenerative treatments, which are non-surgical procedures done in the clinic. Medical providers means the clinicians who do your exam and the procedure. Options may include PRP or concentrated PRP. For both, blood is taken from you and prepared there. A clinician then guides a needle into the aching joint.

You pay nothing for the consultation. Take notes about your worst soreness, along with your medicine list and X-ray report. Ask why PRP fits the cause shown by your exam. Your exam could show that home exercise, physical therapy, medicine, or surgery advice fits better.

If surgery has come up, ask how office care may affect its timing.

Sources

1. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

3. In a prospective randomized trial of 90 patients with Kellgren-Lawrence grade 1-3 knee osteoarthritis, bone marrow aspirate concentrate produced outcomes equivalent to - not better than - leukocyte-rich platelet-rich plasma through 24 months.

   Anz AW, et al. — Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 2 Years: A Prospective Randomized Trial. Am J Sports Med, 2022. DOI: 10.1177/03635465211072554.

4. A systematic review and meta-analysis of 27 Level I studies (1,042 PRP, 226 BMAC, 1,128 hyaluronic acid patients) found PRP and BMAC both outperformed hyaluronic acid on WOMAC, VAS and subjective IKDC scores - note the BMAC evidence base is roughly one fifth the size of the PRP one.

   Belk JW, et al. — Patients With Knee Osteoarthritis Who Receive Platelet-Rich Plasma or Bone Marrow Aspirate Concentrate Injections Have Better Outcomes Than Patients Who Receive Hyaluronic Acid: Systematic Review and Meta-analysis. Arthroscopy, 2023. DOI: 10.1016/j.arthro.2023.03.001.

5. A Bayesian network meta-analysis of 48 randomized trials covering 9,338 knees found hyaluronic acid and PRP significantly improved pain versus placebo, and that BMAC accounted for only 2.5 percent of the studied injections - the thinnest evidence base of the four comparators.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

6. A 2024 systematic review of 8 Level I randomized trials in 937 patients found bone marrow aspirate concentrate improved pain and function versus baseline from one month, but the comparative advantage over other injections was inconsistent across timepoints.

   Han JH, et al. — Bone Marrow Aspirate Concentrate Injections for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials. Orthop J Sports Med, 2024. DOI: 10.1177/23259671241296555.

7. A network meta-analysis of 79 randomized trials in 8,761 patients ranked the intra-articular injectables for knee osteoarthritis on VAS and WOMAC at 1, 3, 6 and 12 months, placing the cell-based options within a crowded field rather than above it.

   Anil U, et al. — The efficacy of intra-articular injections in the treatment of knee osteoarthritis: A network meta-analysis of randomized controlled trials. Knee, 2021. DOI: 10.1016/j.knee.2021.08.008.

8. A phase III double-blind placebo-controlled trial in 261 patients with Kellgren-Lawrence grade 3 knee osteoarthritis tested a single injection of autologous culture-expanded adipose-derived mesenchymal stem cells - a product that cannot legally be sold outside a clinical trial in the United States because culture expansion is more than minimal manipulation.

   Kim KI, et al. — Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial. Am J Sports Med, 2023. DOI: 10.1177/03635465231179223.

9. 21 CFR 1271.10(a) sets the four criteria a human cell or tissue product must meet to be regulated SOLELY under section 361 of the Public Health Service Act: it must be minimally manipulated; intended for homologous use only, as reflected by labeling and advertising; not combined with another article beyond water, crystalloids or a preserving agent; and either have no systemic effect and not depend on the metabolic activity of living cells, or else be for autologous use, use in a close blood relative, or reproductive use.

   US Code of Federal Regulations, Title 21 — 21 CFR 1271.10 - Are my HCT/P's regulated solely under section 361 of the PHS Act. , 2004.

10. On 27 September 2024 the Ninth Circuit held in United States v. California Stem Cell Treatment Center that stromal vascular fraction produced by enzymatically digesting a patient's own fat IS a drug under the Federal Food, Drug, and Cosmetic Act, and that the same surgical procedure exception does not apply because the removed fat and the implanted SVF are not the same thing. The district court's ruling for the clinics was reversed.

    United States Court of Appeals for the Ninth Circuit — United States v. California Stem Cell Treatment Center, Inc., No. 22-56014 (9th Cir. Sept. 27, 2024). , 2024.

11. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

    US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.